CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Combination therapy of the EZH2 inhibitor GSK126 and the PARP inhibitor Olaparib shows in vivo synergy in a patient-derived xenograft model of BRCA1-deficient breast cancer
DOI 10.1055/s-0034-1388546
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Puppe, P ter Brugge, M Seressi, O van Tellingen, E van der Burg, U Boon, P Bouwman, P Mallmann, R Schmutzler, M van Lohuizen, J Jonkers
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Current treatment options for BRCA1-deficient breast cancer are limited highlighting the need for novel targeted therapies. Our group previously demonstrated that EZH2 is overexpressed in BRCA1-deficient breast tumors and a promising target for this subtype. EZH2 is the catalytic subunit of polycomb repressive complex 2 and involved in gene silencing through methylation of histone H3K27. Recently, GSK126…
Zitieren
Zitierempfehlung
J Puppe, P ter Brugge, M Seressi, O van Tellingen, E van der Burg, U Boon, P Bouwman, P Mallmann, R Schmutzler, M van Lohuizen, J Jonkers (2014) Combination therapy of the EZH2 inhibitor GSK126 and the PARP inhibitor Olaparib shows in vivo synergy in a patient-derived xenograft model of BRCA1-deficient breast cancer. Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-0034-1388546
Mit CareLit weiterarbeiten